David Tuveson

Group Leader

Research Group Home Page:: Tuveson Group

Work address:: Cancer Research UK Cambridge Institute University of Cambridge Li Ka Shing Centre Robinson Way Cambridge CB2 0RE

Publications:: Identification of novel vascular projections with cellular trafficking abilities on the microvasculature of pancreatic ductal adenocarcinoma.

E-pub date: 01 Jun 2015; BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model.

E-pub date: 31 Jan 2015; p53 mutations change phosphatidylinositol acyl chain composition.

E-pub date: 31 Dec 2014; ADAM8 as a drug target in pancreatic cancer.

E-pub date: 31 Dec 2014; Organoid models of human and mouse ductal pancreatic cancer.

E-pub date: 31 Dec 2014; The RAS and YAP1 dance, who is leading?

E-pub date: 31 Oct 2014; Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions.

E-pub date: 01 Jul 2013; Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer.

E-pub date: 31 Jan 2013; Corrigendum: The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma.

E-pub date: 31 Dec 2012; Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes.

E-pub date: 31 Oct 2012; The pancreas cancer microenvironment.

E-pub date: 31 Jul 2012; Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice.

E-pub date: 01 Jun 2012; What we have learned about pancreatic cancer from mouse models.

E-pub date: 01 May 2012; The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma.

E-pub date: 31 Mar 2012; nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.

E-pub date: 31 Mar 2012; Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma.

E-pub date: 12 Mar 2012; Predictive in vivo animal models and translation to clinical trials.

E-pub date: 01 Mar 2012; Cellular features of senescence during the evolution of human and murine ductal pancreatic cancer.

E-pub date: 29 Feb 2012; Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials.

E-pub date: 31 Jan 2012; Understanding metastasis in pancreatic cancer: a call for new clinical approaches.

E-pub date: 31 Dec 2011; Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice.

E-pub date: 01 Dec 2011; A novel method for quantification of gemcitabine and its metabolites 2′,2′-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy.

E-pub date: 01 Nov 2011; SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia.

E-pub date: 01 Nov 2011; Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-β-catenin signaling to slow tumor progression.

E-pub date: 01 Oct 2011; In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma.

E-pub date: 30 Sep 2011; C-Raf is required for the initiation of lung cancer by K-Ras(G12D).

E-pub date: 01 Jul 2011; Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis.

E-pub date: 30 Jun 2011; Stromal biology and therapy in pancreatic cancer.

E-pub date: 01 Jun 2011; Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma.

E-pub date: 31 Dec 2010; Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha.

E-pub date: 05 Nov 2010; Deploying mouse models of pancreatic cancer for chemoprevention studies.

E-pub date: 01 Nov 2010; Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer.

E-pub date: 31 Oct 2010; C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).

E-pub date: 31 Oct 2009; RAS in cellular transformation and senescence.

E-pub date: 01 Sep 2009; Finding and killing the CRABs of pancreatic cancer.

E-pub date: 01 Sep 2009; Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.

E-pub date: 12 Jun 2009; An shRNA silencing a non-toxic transgene reduces nutrient consumption and increases production of adenoviral vectors in a novel packaging cell.

E-pub date: 01 May 2009; Modelling oncogenic Ras/Raf signalling in the mouse.

E-pub date: 01 Feb 2009; The use of GEM models for experimental cancer therapeutics.

E-pub date: 01 Sep 2008; K-Ras-driven pancreatic cancer mouse model for anticancer inhibitor analyses.

E-pub date: 01 Aug 2008; A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.

E-pub date: 31 Jul 2008; Dynamics of the immune reaction to pancreatic cancer from inception to invasion.

E-pub date: 30 Sep 2007; Maximizing mouse cancer models.

E-pub date: 01 Sep 2007; Requirement for Rac1 in a K-ras induced lung cancer in the mouse.

E-pub date: 31 Aug 2007; The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression.

E-pub date: 30 Jun 2007; Expression of oncogenic K-ras from its endogenous promoter leads to a partial block of erythroid differentiation and hyperactivation of cytokine-dependent signaling pathways.

E-pub date: 31 May 2007; Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas.

E-pub date: 01 Mar 2007; Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis.

E-pub date: 28 Feb 2007; Restoration of p53 function leads to tumour regression in vivo.

E-pub date: 31 Jan 2007; Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885.

E-pub date: 30 Nov 2006; The use of targeted mouse models for preclinical testing of novel cancer therapeutics.

E-pub date: 31 Aug 2006; Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo.

E-pub date: 31 Aug 2006; Physiological analysis of oncogenic K-ras.

E-pub date: 01 Aug 2006; Mist1-KrasG12D knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma and hepatocellular carcinoma.

E-pub date: 31 Dec 2005; Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations.

E-pub date: 31 Dec 2005; Pancreatic cancer in mice and man: the Penn Workshop 2004.

E-pub date: 31 Dec 2005; The differential effects of mutant p53 alleles on advanced murine lung cancer.

E-pub date: 31 Oct 2005; ATP citrate lyase inhibition can suppress tumor cell growth.

E-pub date: 01 Oct 2005; Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development.

E-pub date: 31 Aug 2005; Ductal pancreatic cancer in humans and mice.

E-pub date: 01 Aug 2005; Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice.

E-pub date: 01 May 2005; VAV1: a new target in pancreatic cancer?

E-pub date: 01 May 2005; Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.

E-pub date: 28 Feb 2005; Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.

E-pub date: 30 Nov 2004; Twist induces an epithelial-mesenchymal transition to facilitate tumor metastasis.

E-pub date: 01 Nov 2004; Detecting and diagnosing ampullary neoplasms.

E-pub date: 01 Jul 2004; Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects.

E-pub date: 01 Apr 2004; Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease.

E-pub date: 01 Feb 2004; Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.

E-pub date: 31 Dec 2003; Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse.

E-pub date: 01 Dec 2003; Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

E-pub date: 30 Nov 2003; BRAF as a potential therapeutic target in melanoma and other malignancies.

E-pub date: 31 Aug 2003; Targeting oncogene dependence and resistance.

E-pub date: 01 May 2003; Ras redux: rethinking how and where Ras acts.

E-pub date: 01 Feb 2003; In search of an early warning system for pancreatic cancer.

E-pub date: 01 Jan 2003; Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

E-pub date: 31 Jul 2002; Technologically advanced cancer modeling in mice.

E-pub date: 01 Feb 2002; Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

E-pub date: 30 Nov 2001; STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications.

E-pub date: 31 Jul 2001; Signal transduction pathways in sarcoma as targets for therapeutic intervention.

E-pub date: 01 Jul 2001; Somatic activation of the K-ras oncogene causes early onset lung cancer in mice.

E-pub date: 31 Mar 2001; Modeling human lung cancer in mice: similarities and shortcomings.

E-pub date: 31 Aug 1999; CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase.

E-pub date: 30 Apr 1993; Molecular interactions of complement receptors on B lymphocytes: a CR1/CR2 complex distinct from the CR2/CD19 complex.

E-pub date: 30 Apr 1991; Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19.

E-pub date: 31 Dec 1990; Show all Hide all

David Tuveson

Group Leader

Identification of novel vascular projections with cellular trafficking abilities on the microvasculature of pancreatic ductal adenocarcinoma.

BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model.

p53 mutations change phosphatidylinositol acyl chain composition.

ADAM8 as a drug target in pancreatic cancer.

Organoid models of human and mouse ductal pancreatic cancer.

The RAS and YAP1 dance, who is leading?

Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions.

Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer.

Corrigendum: The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma.

Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes.

The pancreas cancer microenvironment.

Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice.

What we have learned about pancreatic cancer from mouse models.

The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma.

nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.

Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma.

Predictive in vivo animal models and translation to clinical trials.

Cellular features of senescence during the evolution of human and murine ductal pancreatic cancer.

Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials.

Understanding metastasis in pancreatic cancer: a call for new clinical approaches.

Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice.

A novel method for quantification of gemcitabine and its metabolites 2′,2′-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy.

SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia.

Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-β-catenin signaling to slow tumor progression.

In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma.

C-Raf is required for the initiation of lung cancer by K-Ras(G12D).

Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis.

Stromal biology and therapy in pancreatic cancer.

Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma.

Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha.

Deploying mouse models of pancreatic cancer for chemoprevention studies.

Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer.

C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).

RAS in cellular transformation and senescence.

Finding and killing the CRABs of pancreatic cancer.

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.

An shRNA silencing a non-toxic transgene reduces nutrient consumption and increases production of adenoviral vectors in a novel packaging cell.

Modelling oncogenic Ras/Raf signalling in the mouse.

The use of GEM models for experimental cancer therapeutics.

K-Ras-driven pancreatic cancer mouse model for anticancer inhibitor analyses.

A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.

Dynamics of the immune reaction to pancreatic cancer from inception to invasion.

Maximizing mouse cancer models.

Requirement for Rac1 in a K-ras induced lung cancer in the mouse.

The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression.

Expression of oncogenic K-ras from its endogenous promoter leads to a partial block of erythroid differentiation and hyperactivation of cytokine-dependent signaling pathways.

Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas.

Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis.

Restoration of p53 function leads to tumour regression in vivo.

Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885.

The use of targeted mouse models for preclinical testing of novel cancer therapeutics.

Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo.

Physiological analysis of oncogenic K-ras.

Mist1-KrasG12D knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma and hepatocellular carcinoma.

Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations.

Pancreatic cancer in mice and man: the Penn Workshop 2004.

The differential effects of mutant p53 alleles on advanced murine lung cancer.

ATP citrate lyase inhibition can suppress tumor cell growth.

Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development.

Ductal pancreatic cancer in humans and mice.

Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice.

VAV1: a new target in pancreatic cancer?

Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.

Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.

Twist induces an epithelial-mesenchymal transition to facilitate tumor metastasis.

Detecting and diagnosing ampullary neoplasms.

Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects.

Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease.

Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.

Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse.

Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.

BRAF as a potential therapeutic target in melanoma and other malignancies.

Targeting oncogene dependence and resistance.

Ras redux: rethinking how and where Ras acts.

In search of an early warning system for pancreatic cancer.

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Technologically advanced cancer modeling in mice.

Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.